
ãã¡ã€ã¶ãŒãšæ¿åºã®æ©å¯ææžã«ãããCOVIDã¯ã¯ãã³æ¥çš®ãæäœäŸåæ§å¢åŒ·çãV-AEDãAIDSãåŒãèµ·ãããæ°çŸäžäººããçªç¶æ»ãããããšãæããã«ãªã£ãã
å èšäºã¯ãã¡ããã/Click here to read the original article.
æ©å¯ææžã«ãããšãCOVID-19ã¯ã¯ãã³ã®ååæ¥çš®ããæ°ã¶æä»¥å
ã«ãäžéšã®äººãæäœäŸåæ§å¢åŒ·çïŒADEïŒãã¯ã¯ãã³é¢é£å¢åŒ·çïŒVAEDïŒãçºçããŠããããšã倿ããŸããã
ããã«ãååæ¥çš®ããããã5ãµæåŸã«ãè¬ã®åŸå€©æ§å
ç«äžå
šçå矀ãçºçããŠããããšãå
¬åŒææžãã倿ããŠããŸãã
ãã®ããšã¯ãCOVID-19ã¯ã¯ãã³ã®æ®åã«äŒŽããç±³åœãè±åœããªãŒã¹ãã©ãªã¢ãã«ããããšãŒããããªã©äžçååœã§æ°çŸäžäººãè¬ã®æ¥æ»ãéããããšããæ¿åºã®å
¬åŒèšé²ã§ç¢ºèªãããŠããããšã®èª¬æã«ããªãã
æäœäŸåæ§å¢åŒ·çïŒADEïŒãšã¯ã¯ãã³é¢é£å¢åŒ·çïŒVAEDïŒ.ã¯ãã¯ã¯ãã³æ¥çš®åŸã«èµ·ããããæ·±å»ãªæå®³äºè±¡ã§ããã
ADEãšVAEDã¯ãå®å šãªå ç«ãåŸãããªãã¯ã¯ãã³ãæ¥çš®ããåŸã«ãå人ãçæã®ã³ãã19ãŠã€ã«ã¹ãªã©ã®ç åäœã«ãããããå Žåã«èµ·ããããã
ãã®ãããªå Žåãã¯ã¯ãã³ã«ãã£ãŠèªå°ãããæäœã¯ãå®éã«ç åäœã®çŽ°èææèœåãé«ããã¯ã¯ãã³ãæ¥çš®ããªãã£ãå Žåãããéçåããå¯èœæ§ããããŸãã
ã¯ã¯ãã³ãADEãŸãã¯VAEDãåŒãèµ·ããå Žåãå ¬è¡è¡çã«é倧ãªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
äœããããŸããã¯ã¯ãã³ãæ¥çš®ããŠADEãŸãã¯VAEãçºçããå人ã¯ãé節ãªç æ°ã«èŠãã¿ãå Žåã«ãã£ãŠã¯æ»äº¡ããããšããããŸãã
ADEãšé¢é£ããéå»ã®ã¯ã¯ãã³ã®äžäŸãšããŠããã³ã°ç±ã¯ã¯ãã³ããããŸããå€ãã®å Žåããã³ã°ã¯ã¯ãã³ãæ¥çš®ãããã®åŸãã³ã°ãŠã€ã«ã¹ã«ææãã人ã¯ãããéçåããå ¥é¢ãæ»äº¡ã®ãªã¹ã¯ãé«ãŸã£ãã
åæ§ã«ãåŒåžåšåèäœãŠã€ã«ã¹ïŒRSVïŒããã³HIVã®ã¯ã¯ãã³ãæ¥çš®ãã人ã«ãããŠããADEãå ±åãããŠããŸãã
ADEãŸãã¯VAEã«ãã£ãŠæªåããå¯èœæ§ã®ããçŽ°èææçã®äžäŸãšããŠã溶é£èAïŒstrep AïŒææçãæããããŸããæº¶é£èAã¯ãã®ã©ã®çã¿ãèºçãæè¡çãªã©ãããŸããŸãªç æ°ãåŒãèµ·ããå¯èœæ§ããã现èã®äžçš®ã§ãããã®å¬ãAåæº¶è¡æ§ã¬ã³ãµçèææçãåã©ããã¡ã®åœã奪ã£ãŠããããšã¯ããã¥ãŒã¹ãªã©ã§ãåç¥ã§ãããã

ãã®äºå®ãè£ä»ããæãéèŠãªèšŒæ ã¯ãã³ããã19ã®ã¯ã¯ãã³æ¥çš®ãå ç«ç³»ãæå·ããäœããã®æ°ãã圢ã®åŸå€©æ§å ç«äžå šçå矀ãåŒãèµ·ããå¯èœæ§ãããããšã蚌æããæ¿åºã®å ¬åŒå ±åæžã§ããã
ADEãšVAEDããåŸå€©æ§å ç«äžå šçå矀ïŒAIDSïŒã«èŠããããããªç倧ãªå ç«ç³»é害ãåŒãèµ·ããå¯èœæ§ã¯ååã«ãããŸãã
AIDSã§ã¯ãå ç«ç³»ãèããäœäžããææçããã®ä»ã®ç æ°ã«ãããããããªã£ãŠããŸããåæ§ã«ãADEãVAEDã®çºçã¯ãå ç«ç³»ãžã®ãã¡ãŒãžã«ã€ãªãããææçãä»ã®ç æ°ã®ãªã¹ã¯ãé«ããªãå¯èœæ§ããããŸãã
ãšã€ãºã«å¹æµããé節ãªçŸæ£ã®ãªã¹ã¯ã«å ããADEããã³VAEDã¯ãç¹å®ã®çã®çºçãªã¹ã¯ãé«ããå¯èœæ§ããããŸããäŸãã°ãADEã¯ããçš®ã®ãªã³ãè «ã®çºçãªã¹ã¯ãé«ããå¯èœæ§ãããããšããããã€ãã®ç ç©¶ã§ç€ºåãããŠããŸãã
ãããã®æå®³äºè±¡ã®çºçã¯ãçºçããå人ã«å£æ» çãªçµæããããããæ©å¯ææžãå ¬åŒææžã«ãããCOVID-19ã¯ã¯ãã³ãåå ã§ADEãšVAEDãçºçããäžçäžã§æ°ãã圢ã®åŸå€©æ§å ç«äžå šçåçŸ€ãšæ°çŸäžäººã®éå°æ»äº¡ã«ã€ãªãã£ãããšã蚌æãããŠããŸãã
2009幎ã«å²äžæå€§ã®å»çè©æ¬ºåè§£éãšåäºçœ°ã®å¯Ÿè±¡ãšãªã£ããã¡ã€ã¶ãŒç€Ÿã¯ãã³ããã19ãšããåã®ç·æ¥äœ¿çšèš±å¯ã®ããšã§äžè¬å€§è¡ã«æäžãããå²äžåã®mRNAéºäŒåæ²»çæ³šå°ãéçºããäŒç€Ÿã§ããããŸããããã®ã³ããã19 mRNAéºäŒåæ²»çãã¯ã¯ãã³é¢é£åŒ·åç ãåŒãèµ·ãããããããªãããšããå¿ æ»ã«å ¬è¡šããªãããã«ããŠããæ©å¯ææžã§èªããŠããŸãã
ç±³åœé£åå»è¬åå±ïŒFDAïŒã¯ã2020幎12æ11æ¥ã«ããã108æ¥éã®å®å šæ§å¯©æ»ã§æ³šå°ãæ¿èªããã«ããããããããã¡ã€ã¶ãŒã®COVID-19ã¯ã¯ãã³ã®å®å šæ§ããŒã¿ã®å ¬éã75幎éãé ãããããšããŸããã
FDAã¯åœåãPublic Health and Medical Professionals for TransparencyïŒPHMPTïŒã«ä»£ãã£ãŠæåºãããå®å šæ§ããŒã¿ãæ±ããæ å ±å ¬éïŒFOIïŒè«æ±ãžã®åçãšããŠãæ¯æ500ããŒãžãå ¬éããçšæããããšè¿°ã¹ãŠããŸããã
ãã®ä»£ããã2022幎1æäžæ¬ãé£éŠå€äºããŒã¯ã»ããããã³ã¯ãæ¯æ55,000ããŒãžãå ¬éããããåœããã圌ãã¯1ææ«ãŸã§ã«12,000ããŒãžãå ¬éããŸããã
ãã以æ¥ãPHMPTã¯ãã¹ãŠã®ææžããŠã§ããµã€ãã«æ²èŒããŠããŸãã
ææ°ã®ããŒã¿ãã³ãã«å«ãŸããææžã®1ã€ããreissue_5.3.6 postmarketing experience.pdfãã§ãããã®ææžã®11ããŒãžã«ãã衚5ã«ã¯ãéèŠãªæœåšçãªã¹ã¯ãã瀺ãããŠããããã®ãªã¹ã¯ã¯ãã¯ã¯ãã³é¢é£åŒ·ååçŸæ£ïŒVAEDïŒãã¯ã¯ãã³é¢é£åŒ·ååå埩æ§çŸæ£ïŒVAERDïŒãå«ãããšèšèŒãããŠããŸãã

ãã¡ã€ã¶ãŒç€Ÿã¯æ©å¯ææžã§ã2021幎2æ28æ¥ãŸã§ã«ãã¯ã¯ãã³é¢é£äº¢é²çã瀺ã317ã®æœåšçé¢é£äºè±¡ãå ±åãã138ä»¶ã®äºäŸãåãåã£ããšäž»åŒµããããã®ãã¡71ä»¶ã¯å»åŠçã«éèŠã§ããã8ä»¶ã®é害ãããããã13ä»¶ã¯çåœãè ããäºè±¡ã§ããã138人ã®ãã¡38äººãæ»äº¡ããŸããã
138人ãå ±åãã317ã®é¢é£äºè±¡ã®ãã¡ã135ã¯ãè¬å€ç¡å¹ãã53ã¯ãåŒåžå°é£ãã23ã¯ãCovid-19èºçãã8ã¯ãåŒåžäžå šãã7ã¯ãçæ£ããšè¡šç€ºãããã
ãŸãããã¡ã€ã¶ãŒç€Ÿã¯ãã¯ã¯ãã³æ¥çš®åŸã«Covid-19ã確èªããã101人ã®è¢«éšè ã®ãã¡75人ããå ¥é¢ãé害ãçåœãè ããçµæããŸãã¯æ»äº¡ã«è³ãéçã§ããããšãèªããŸããã
ãããããã¡ã€ã¶ãŒç€Ÿã¯ãFDAã«æåºããå®å šæ§ããŒã¿ãã€ãŸãç·æ¥äœ¿çšèš±å¯ãåŸãŠäœååãã«ãã®å©çãåŸãããã«å¿ èŠãªããŒã¿ã®ããã«ãã75äŸã®ãã¡VAEDãšæå®ã§ãããã®ã¯ãªãããšæå®ããã®ã§ããã
ãããããã¡ã€ã¶ãŒã¯ãã®åŸãçŸåšã®ãšããã³ã¹ã«åºã¥ããVAEDã¯çè«çãªãªã¹ã¯ãšããŠæ®ã£ãŠããããšã確èªããŸããã
ãã®æ©å¯ããŒã¿ã¯ãã³ããã-19泚å°å€ãç·æ¥äœ¿çšèš±å¯ãåŸãã¹ãã§ã¯ãªãã£ãããšããããŠFDAããã®æ°åãç®ã«ãããããã«æµéããæ€éãã¹ãã ã£ãããšã蚌æããŠããŸãã
ãããŠãã³ããã-19ã¯ã¯ãã³æ¥çš®ã«ããADEãšVADEãããšã€ãºã«å¹æµããå ç«ç³»é害ãåŒãèµ·ãããããšãç¥ãæ¹æ³ãããã«ãããŸãã
è±åœå¥åº·å®å šä¿éå±ïŒUKHSAïŒã¯ãã€ãŠæ¯é±ã¯ã¯ãã³ã»ãµãŒãã€ã©ã³ã¹ã»ã¬ããŒããçºè¡šããŠãããåã¬ããŒãã«ã¯ã¯ã¯ãã³æ¥çš®ç¶æ³å¥ã«Covid-19ã®çäŸãå ¥é¢ãæ»äº¡ã«é¢ãã4é±éåã®ããŒã¿ãå«ãŸããŠããŸããã
æã ã¯ãã³ããã19ã¯ã¯ãã³ãã¯ã¯ãã³æ¥çš®è ã®å ç«ç³»ã«äžãã圱é¿ãæç¢ºã«ææ¡ããããã«ã2021幎8æ16æ¥ãã2022幎1æ2æ¥ãŸã§ã®ããŒã¿ãå«ãããããã®å ¬è¡šãããã¯ã¯ãã³ãµãŒãã€ã©ã³ã¹å ±åæžã®ãã¡5ã€ãåæãããšãããæ¬¡ã®ãããªããšã倿ããã
ä»åã®èª¿æ»ã«äœ¿çšããUKHSAã®ã¯ã¯ãã³ãµãŒãã€ã©ã³ã¹ã¬ããŒãã¯ããã¹ãŠãã¡ãã§ã芧ããã ããŸãã
âCovid-19 Vaccine Surveillance Report â Week 37â (Published by PHE)
âCovid-19 Vaccine Surveillance Report â Week 41â (Published by UKHSA)
âCovid-19 Vaccine Surveillance Report â Week 45â (Published by UKHSA)
âCovid-19 Vaccine Surveillance Report â Week 49â (Published by UKHSA)
âCovid-19 Vaccine Surveillance Report â Week 1 â 2022â (Published by UKHSA)
ãã¡ã€ã¶ãŒç€Ÿè£œã³ããã19mRNA泚å°ã®ã¯ã¯ãã³å¹æã¯95ïŒ ãšèšãããŸãããã
以äžã®ã°ã©ãã¯ã21幎8æ16æ¥ãã22幎1æ2æ¥ãŸã§ã®5ã¶æéãå幎霢局ã«ãããæå¥ã®ã¯ã¯ãã³å¹æã®å¢æžã瀺ãããã®ã§ããã

æåã®ããŒã¹ã¿ãŒã·ã§ããã¯2021幎ã®37é±ç®ã«å®æœããããã®ã°ã©ãã¯ããã®åŸã®2ã¶æéã§ã¯ã¯ãã³å¹æã®ããŒã¹ãããããããããšãæç¢ºã«ç€ºããŠããŸããããããæ®å¿µãªããããã®ããŒã¹ããããã«çæéã§ãã£ããã瀺ããŠããã49é±ç®ãã52é±ç®ã«ãããŠãã³ããã19ã¯ã¯ãã³ã®æå¹æ§ã¯æãããã¬ãã«ãŸã§äœäžããŠããããšãããããŸãã
çŸå®ã®ã¯ã¯ãã³å¹æã¯ã12æ6æ¥ãã1æ2æ¥ã«ãããŠã70æ³ä»¥äžãé€ããã¹ãŠã®å¹Žéœ¢å±€ã§ãããŸã§ã§æãäœãã¬ãã«ãŸã§äœäžããŸãããã70æ³ä»¥äžã§ã¯ãŸã ãã€ãã¹å¹æã«èœã¡èŸŒãã§ããŸãã
40ïœ69æ³ã§ã¯ããããªãããŒã¹ããæåŸ ããããå®çŸããã代ããã«40ïœ49æ³ã§-151%ãŸã§äœäžããã¯ã¯ãã³å¹æã®å€§è»¢èœãèšé²ãããã
ãŸãã30ïœ39æ³ã®å¹Žéœ¢å±€ã§ã¯ã49é±ç®ã«æ°çŸäžäººã«ããŒã¹ã¿ãŒãžã£ããæäžãããã«ãããããããã¯ã¯ãã³å¹æã¯ãã€ãã¹123%ã«èœã¡èŸŒãã ã
ããã¯ãããªããèšããã95ïŒ ã®æå¹æ§ãšã¯çšé ããã®ã§ãã
ããããå®éã«ã¯ã¯ãã³å¹æã®ãã©ã¹ã»ãã€ãã¹ã¯ã©ã®ãããªæå³ãæã€ã®ã§ããããã
ã¯ã¯ãã³ã¯ããŠã€ã«ã¹ã«ããæ»æãã·ãã¥ã¬ãŒãããŠãå ç«ç³»ãåºæ¿ãããŠã€ã«ã¹ã«ææãããã®ããã«åå¿ãããããšã§å¹æãçºæ®ããŸãããã®çµæããŠã€ã«ã¹ã«å¯Ÿããèªç¶å ç«ãç²åŸãããŸã§ã«å ç«ç³»ãéãããããšèããããŠããŸãã
ãããã£ãŠãã¯ã¯ãã³ã®å¹æãšã¯ãã¯ã¯ãã³æ¥çš®è ã®å ç«ã·ã¹ãã ã®æ§èœãšãã¯ã¯ãã³æªæ¥çš®è ã®å ç«ã·ã¹ãã ã®æ§èœãæ¯èŒãããã®ã§ãããšèšããŸãã
UKHSAãçºè¡šããããŒã¿ã¯ãã³ããã19泚å°ã®çŸå®ã®å¹æïŒæ¬åœã¯å ç«ç³»ã®æ§èœã®ææšïŒãçæéã§èããè¡°ããããšã確èªãããã®ã§ãã
ããããã¯ã¯ãã³æ¥çš®è ã«ãšã£ãŠã¯æ®å¿µãªããšã«ãå ç«ç³»ãã¯ã¯ãã³æ¥çš®åãšåãç¶æ ã«æ»ãã®ã§ã¯ãªããå ç«ç³»ã®æ§èœãæ¥éã«äœäžãå§ãã3itãã¯ã¯ãã³æ¥çš®è ã«æ¯ã¹ãŠå£ã£ãŠããŸãã
ããããè±åœæ¿åºã®ããŒã¿ã¯ãã¯ã¯ãã³ã®ããŒã¹ã¿ãŒæäžãçæçã«å ç«ç³»ãé«ããããšãã§ããããšã蚌æããŠããŸãã
ããããæ®å¿µãªããšã«ããã®åãããŒã¿ã¯ãå ç«ã·ã¹ãã ã®æ§èœã¯ããã®åŸãããŒã¹ã¿ãŒæäžåãããããã«æ¥éã«äœäžãå§ããããšã瀺ããŠããŸãã
ãããã£ãŠããã®ããŒã¿ã¯ãã¯ã¯ãã³æ¥çš®ãåãã人ã ãããã®å ç«ã·ã¹ãã ãã倱æããªãçšåºŠã«ããããã¯ã¯ãã³æ¥çš®ãåããŠããªã人ã ãããå£ãçšåºŠã«é«ããããã«ãããŒã¹ã¿ãŒæ³šå°ãç¡éã«ç¹°ãè¿ãå¿ èŠãããããšã瀺åããŠããã®ã§ãã

ADEãŸãã¯VAEDã¯ãŸããéå°æ»äº¡ã®å¢å ã«ã€ãªããå¯èœæ§ããããŸããéå°æ»äº¡ãšã¯ãããéå£ã§äºæ³ãããæ»äº¡æ°ãè¶ ããŠçºçããæ»äº¡ã®ããšã§ãã
ããã¯ãADEãVAEDãããé節ãªçŸç ãæ»äº¡ãªã¹ã¯ã®å¢å€§ãåŒãèµ·ãããã¯ã¯ãã³æ¥çš®ããŠããªãéå£ã§äºæ³ãããæ»äº¡æ°ãããå€ãæ»äº¡æ°ã«ã€ãªããå¯èœæ§ãããããã§ãã
ãã®ããšã¯ãæ²åçãªããšã«ãCOVID-19ã¯ã¯ãã³ã®åºç¯ãªé åžããã£ããã«ãäžçååœã§äœçŸäžäººãã®äººã ãè¬ã®æ¥æ»ãéããããšããæ¿åºã®å ¬åŒèšé²ã§ç¢ºèªãããŠããããšã®èª¬æã«ããªãã
ã¢ã¡ãªã«ãã«ããããªãŒã¹ãã©ãªã¢ããã¥ãŒãžãŒã©ã³ããã€ã®ãªã¹ããšãŒãããã®ã»ãšãã©ã®åœã®æ¿åºãçºè¡šããå ¬åŒå ±åæžã«ãããšãã³ããã19ã®å€§éæ¥çš®ä»¥éã180äžäººã®éå°æ»äº¡ãèšé²ãããããšã確èªãããŠããŸãã
ã€ã®ãªã¹ããšãŒãããã®ããã«ãæ»äº¡ã«é¢ããããŒã¿ãéææ§ãæã£ãŠå ¬è¡šããŠããåœããããŸãããããã圌ãã¯ãã®æ°åãæããã«ããããšãçç±ã«ãç©æ¥µçãªå ¬è¡šãæåŠããŠããã
ããããã¢ã¡ãªã«ã®ããã«ãæ»äº¡ããŒã¿ã極åé ãããšããåœãããã
ããããç§ãã¡ã¯ãçµæžååéçºæ©æ§ïŒOECDïŒãšããçµç¹ã®ãŠã§ããµã€ãã®å¥¥æ·±ãã«é ããããäžçã®15ïŒ ã®åœã®ããŒã¿ãã€ãã«èŠã€ããããšã«æåããã
OECDã¯ãçµæžçºå±ãšäžç貿æãä¿é²ããããã«1961幎ã«èšç«ããã38ã«åœãå çããæ¿åºéçµç¹ã§ããããããŠãªãããéå°æ»äº¡ã«é¢ããè±å¯ãªããŒã¿ãä¿æããŠããã®ã§ãããã®ããŒã¿ã¯ããã¡ãã§ã芧ããã ããŸãã
次ã®ã°ã©ãã¯ããªãŒã¹ãã©ãªã¢ãã«ããããã¥ãŒãžãŒã©ã³ããã€ã®ãªã¹ãã¢ã¡ãªã«ã®5ã«åœãšããšãŒãããã®27ã«åœãããªãæ å ±åçããã¡ã€ãã»ã¢ã€ãºãã®è¶ éæ»äº¡æ°ã«ã€ããŠèª¿ã¹ãçµæã§ãã


çµè«ãšããŠãæäœäŸåæ§å¢åŒ·ïŒADEïŒãšã¯ã¯ãã³é¢é£å¢åŒ·ç ïŒVAEDïŒã¯ãCovid-19ã¯ã¯ãã³æ¥çš®åŸã«èµ·ããããéå€§ãªæå®³äºè±¡ã§ãã
Covid-19ã¯ã¯ãã³ãæ¥çš®ããåäœãç åäœã«ããããããšã倧混乱ã«é¥ãå¯èœæ§ãããããã®ãããªå Žåãã¯ã¯ãã³ã«ãã£ãŠèªå°ãããæäœããç åäœã®çŽ°èææèœåãå®éã«åŒ·åããã¯ã¯ãã³ãæ¥çš®ããªãã£ãå Žåãããéçåããå¯èœæ§ããããŸãã
ADEãVAEDã®çºçã¯ãå人ãšå ¬è¡è¡çã®äž¡æ¹ã«é倧ãªåœ±é¿ãåãŒããŠããŸãã
ADEãŸãã¯VAEDãçºçããå人ã®éçåãæ»äº¡ãªã¹ã¯ã®äžæãããã³ç¹å®ã®çã®çºçãªã¹ã¯ã®äžæãæããŠããã®ã§ãã
ADEãŸãã¯VAEDã®çºçã¯ãéå°æ»äº¡ã®å¢å ã«ãã€ãªãããããã¡ã€ãã»ã¢ã€ãºã諞åœã ãã§180äžäººãè¶ ããŠããŸãã
ã¯ã¯ãã³ã¡ãŒã«ãŒãšå ¬è¡è¡çæ©é¢ã¯ãã¯ã¯ãã³æ¥çš®åŸã®æå®³äºè±¡ã«ã€ããŠåœæ°ãæ³šææ·±ãç£èŠããçºçããåé¡ã«å¯ŸåŠããããã«é©åãªè¡åããšãã¹ãã§ãã£ãã
ããã«ã¯ãã¯ã¯ãã³æ¥çš®ã®æšå¥šäºé ã®æ¹èšãèŠåãæ³šæåèµ·ã®çºä»€ãå Žåã«ãã£ãŠã¯ã¯ã¯ãã³ã®åžå Žããã®æ€å»ãªã©ãå«ãŸããã¯ãã§ãã
ãããã圌ãã¯ãããã®ããšãäœäžã€ããªãã£ãã
ããªããªã®ãïŒã